Wei Yan from Trenton, TN, age 34

Resumes

Graduate Students

View page

Location:

Brooklyn, NY

Industry:

Electrical/Electronic Manufacturing

Work:

New York University
Graduate Students

Wei Yan

View page

Wei Yan

View page

Wei Yan

View page

Wei Yan

View page

Wei Yan

View page

Postdoctoral Researcher - Uams

View page

Work:

Postdoctoral Researcher - Uams

Wei Yan

View page

Location:

United States

Business Records

Name / Title

Company / Classification

Phones & Addresses

Wei Yan
President

Suryani International
Computer Software · Computer Consulting

55 Broad St RM 11A, New York, NY 10004
(212) 344-0383

Wei Yan
Attorney

China Patent & Trademark Agent
Legal Services Office · Offices of Lawyers

55 Broad St, New York, NY 10004
(212) 809-8100, (212) 809-8118

Wei Yan
Principal

Dean International Inc
Business Services at Non-Commercial Site

13522 61 Rd, Flushing, NY 11367

Wei Yan
M

1800DIAPERS, LLC

55 Broad St, New York, NY 10004
245 E 93 St, New York, NY 10128
1100 106 Ave NE, Bellevue, WA 98004
100 Jane St, New York, NY 10014

Publications

Us Patents

Oncolytic Vaccinia Virus Expressing Immune Checkpoint Blockade For Cancer Immunotherapy

View page

US Patent:

20210023151, Jan 28, 2021

Filed:

Mar 12, 2019

Appl. No.:

16/980282

Inventors:

- New York NY, US
Weiyi WANG - New York NY, US
Stewart SHUMAN - New York NY, US
Taha MERGHOUB - New York NY, US
Jedd WOLCHOK - New York NY, US
Wei YAN - Bothell WA, US

Assignee:

MEMORIAL SLOAN KETTERING CANCER CENTER - New York NY

International Classification:

A61K 35/76
C07K 16/28
A61K 9/00

Abstract:

Disclosed herein are methods and compositions related to the treatment, prevention, and/or amelioration of cancer in a subject in need thereof. In particular aspects, the present technology relates to the use of poxviruses, including an engineered attenuated vaccinia vims (VACV) strain comprising a disruption of the N-terminal DNA binding domain of the E3L gene (E3LΔA83N) with a deletion of thymidine kinase (E3LΔ83N-TK) engineered to express an antibody specifically targeting cytotoxic T lymphocyte antigen (E3LΔ83N-TK-anti-CTLA-4), alone or in combination with immune checkpoint blocking agents or immune stimulating agents, as an oncolytic and immunotherapeutic composition. In some aspects, the present technology relates to an E3LΔ83N-TK-anti-CTLA-4 virus further engineered to express human Fms-like tyrosine kinase 3 ligand (hFlt3L) (E3LΔ83N-TK-hFlt3L-anti-CTLA-4). In some embodiments, the engineered viruses are administered to a subject alone or in combination with immune checkpoint blocking agents or immune stimulating agents, as an oncolytic and immunotherapeutic composition.